Hospital
Sarah Bush Lincoln Health Center
Sarah Bush Lincoln Health Center was paid $3.27M by Medicaid between Jan 2018 and Jul 2020, across 139 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 59% of everything it billed.
33Billing provider infoSARAH BUSH LINCOLN HEALTH CENTER
MATTOON, IL 61938
MATTOON, IL 61938
33aNPI1669564662assigned 09/28/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$3.27M
24GClaims160,399
24DCodes billed139
24AFirst – last monthJan 2018 – Jul 2020
Compared with peers
Next to other Psychiatric Hospital Unit providers in Illinois
Rank by total paid#4 of 24
Median peer was paid$554K
This provider vs. median5.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,169 | $991K | |
| 2019 | 79,771 | $1.57M | |
| 2020 | 36,459 | $706K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 59% | 26,131 | 4,024 | $1.94M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5.6% | 4,488 | 1,099 | $184K |
| 97161 | 4.3% | 1,973 | 1,259 | $141K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.0% | 2,098 | 1,885 | $132K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.5% | 1,296 | 952 | $114K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 2,653 | 2,443 | $69K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.8% | 2,639 | 2,417 | $57K |
| 97162 | 1.4% | 624 | 381 | $47K | |
| 92557 | 1.4% | 1,317 | 832 | $45K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 6,738 | 6,241 | $45K |
| 80053 | Comprehensive metabolic panel | 1.3% | 12,230 | 10,250 | $43K |
| 92567 | 1.1% | 2,613 | 1,659 | $37K |
127 more codes
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 665 | $35K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,204 | $22K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,742 | $21K |
| 92579 | <1% | 959 | $20K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,655 | $19K |
| 87070 | <1% | 4,999 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 479 | $13K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 755 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 496 | $12K |
| 80061 | Lipid panel | <1% | 5,666 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 879 | $9K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 899 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,410 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 791 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 710 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,086 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,271 | $7K |
| 87186 | <1% | 1,904 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,314 | $6K |
| V5241 | Dispensing fee, monaural hearing aid, any type | <1% | 28 | $6K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 601 | $6K |
| 87800 | <1% | 817 | $5K | |
| 80074 | <1% | 261 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 39 | $5K |
| 82607 | <1% | 1,496 | $5K | |
| 87653 | <1% | 386 | $5K | |
| 84439 | <1% | 2,120 | $5K | |
| 86038 | <1% | 450 | $5K | |
| 87088 | <1% | 1,403 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 93 | $5K |
| 87522 | Neg quan hep c or qual rna | <1% | 109 | $4K |
| 82728 | <1% | 1,416 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 159 | $4K |
| 87340 | <1% | 746 | $3K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 227 | $3K |
| 82746 | <1% | 680 | $3K | |
| 86901 | <1% | 1,502 | $3K | |
| 73564 | <1% | 279 | $3K | |
| 73610 | <1% | 230 | $3K | |
| 86696 | <1% | 127 | $3K | |
| 84466 | <1% | 1,223 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 62 | $3K |
| 84702 | <1% | 810 | $3K | |
| 73630 | <1% | 279 | $3K | |
| 87081 | <1% | 1,324 | $3K | |
| 86336 | <1% | 177 | $3K | |
| 84403 | <1% | 311 | $3K | |
| 85027 | <1% | 1,522 | $2K | |
| 86592 | <1% | 1,543 | $2K | |
| 72110 | <1% | 142 | $2K | |
| 86141 | <1% | 328 | $2K | |
| 85610 | <1% | 1,524 | $2K | |
| 83516 | <1% | 153 | $2K | |
| 83540 | <1% | 1,295 | $2K | |
| 73110 | <1% | 178 | $2K | |
| 86850 | <1% | 1,538 | $2K | |
| 86695 | <1% | 132 | $2K | |
| 81001 | <1% | 2,327 | $2K | |
| 84153 | <1% | 396 | $2K | |
| 82105 | <1% | 232 | $2K | |
| 84481 | <1% | 602 | $2K | |
| 83735 | <1% | 1,034 | $2K | |
| 74018 | <1% | 140 | $1K | |
| 80076 | <1% | 548 | $1K | |
| 84270 | <1% | 97 | $1K | |
| 86318 | <1% | 180 | $1K | |
| 86762 | <1% | 726 | $1K | |
| 73030 | <1% | 125 | $1K | |
| 86900 | <1% | 1,549 | $1K | |
| 81003 | <1% | 1,529 | $1K | |
| 80306 | <1% | 253 | $1K | |
| 82043 | <1% | 617 | $1K | |
| 86255 | <1% | 197 | $1K | |
| 82570 | <1% | 866 | $1K | |
| 73502 | <1% | 75 | $1K | |
| 73130 | <1% | 119 | $1K | |
| 86140 | <1% | 736 | $960.92 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 12 | $863.59 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 38 | $849.08 |
| 87486 | <1% | 37 | $826.24 | |
| 86431 | <1% | 350 | $769.52 | |
| 97165 | <1% | 74 | $767.04 | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 13 | $752.73 |
| 85652 | <1% | 974 | $726.42 | |
| 87581 | <1% | 37 | $714.82 | |
| 82950 | <1% | 691 | $699.99 | |
| 87205 | <1% | 813 | $695.99 | |
| 82784 | <1% | 112 | $676.35 | |
| 83001 | <1% | 97 | $637.55 | |
| 82677 | <1% | 164 | $627.35 | |
| 87899 | <1% | 76 | $526.71 | |
| 92582 | <1% | 23 | $470.65 | |
| 85007 | <1% | 415 | $394.54 | |
| 84550 | <1% | 321 | $372.33 | |
| 83525 | <1% | 141 | $342.35 | |
| 83690 | <1% | 191 | $335.16 | |
| 87209 | <1% | 34 | $286.13 | |
| 87045 | <1% | 83 | $282.32 | |
| 84703 | <1% | 100 | $261.78 | |
| 80164 | <1% | 74 | $234.07 | |
| 82274 | <1% | 80 | $210.45 | |
| 73140 | <1% | 31 | $202.42 | |
| 87210 | <1% | 166 | $200.67 | |
| 83002 | <1% | 64 | $172.54 | |
| 82550 | <1% | 96 | $166.56 | |
| 82103 | <1% | 21 | $137.92 | |
| 73590 | <1% | 14 | $135.98 | |
| 82150 | <1% | 75 | $134.38 | |
| 80050 | General health panel | <1% | 29 | $127.80 |
| 86706 | <1% | 12 | $123.34 | |
| 87449 | <1% | 33 | $122.92 | |
| 88142 | <1% | 55 | $117.36 | |
| 82947 | <1% | 85 | $88.30 | |
| 82248 | <1% | 51 | $76.43 | |
| 87807 | <1% | 18 | $69.03 | |
| 84146 | <1% | 15 | $65.48 | |
| 87177 | <1% | 33 | $63.09 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,495 | $56.19 |
| 87335 | <1% | 19 | $53.48 | |
| 83880 | <1% | 14 | $51.01 | |
| 86003 | <1% | 12 | $48.73 | |
| 85730 | <1% | 16 | $25.82 | |
| 86308 | <1% | 13 | $11.82 | |
| 89055 | <1% | 14 | $7.25 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 148 | $0.00 |
| 0065U | 0% | 166 | $0.00 | |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISCHER, SEAN (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Sarah Bush Lincoln Health Center | Charleston, IL | $2.38M |
| Sarah Bush Lincoln Health Center | Mattoon, IL | $2.10M |
| Sarah Bush Lincoln Health Center | Vandalia, IL | $1.68M |
| Sarah Bush Lincoln Health Center | Effingham, IL | $653K |
| Sarah Bush Lincoln Health Center | Vandalia, IL | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.